Tenelia Triple Combination Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT02567994

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02567994
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02567994. Randomized; quadruple masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2017-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenelia Triple Combination Study
Acronym
TETRIS
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Teneligliptin
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct02567994
Content hash
cce46ed731176c8ad11e9dd89786c40ebd88379c0342379e6aed94f5ce968eb7